Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
NCT05469061Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2022
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Incidence of translational treatment Adverse Events up to 2 years, Major Pathological Response up to 2 years and 1 more. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05469061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469061.